Sugi Predict

Sugi Predict / Compounds / SCHEMBL21798342

SCHEMBL21798342

SCHEMBL21798342

CCOC(=O)CS(=O)(=O)C(C)(C)COC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.39
▸ GAA P10253 4/20 0.39
▸ MGAM O43451 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ CYP1A2 P05177 1/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.31
▸ LMNA P02545 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ BCL2A1 Q16548 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12144404 0.74 ALDH1A1 (0.33) ALDH1A1
SCHEMBL10420536 0.73 GAA (0.44) KMT2AGAAMGAMSIMGAM2
SCHEMBL8413025 0.69 GAA (0.55) KMT2AGAAMGAMSIMGAM2
SCHEMBL15912147 0.69 GAA (0.48) KMT2AGAAMGAMSIMGAM2
SCHEMBL1128967 0.68 GAA (0.48) KMT2AGAAMGAMSIMGAM2
SCHEMBL6181 0.68 GAA (0.52) KMT2AGAAMGAMSIMGAM2
SCHEMBL11220004 0.68 GAA (0.52) KMT2AGAAMGAMSIMGAM2
SCHEMBL11361701 0.68 GAA (0.52) KMT2AGAAMGAMSIMGAM2
SCHEMBL47545 0.68 GAA (0.52) KMT2AGAAMGAMSIMGAM2
SCHEMBL21798404 0.67 CYP3A4 (0.34) KMT2AGAAALDH1A1CYP1A2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466821-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2025-11-11 — — US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 — — US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 — — US disclosed
EP-3849979-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS Novartis AG (CH) 2021-07-21 — — EP disclosed
CN-112996789-A Antiviral pyridopyrazinedione compounds 诺华股份有限公司 2021-06-18 — — CN disclosed
WO-2020053654-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-19 — — WO disclosed
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466821-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP KMT2A 2738/4885GAA 1363/4885MGAM 3858/4885
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP KMT2A 2738/4885GAA 1363/4885MGAM 3858/4885
US-11072610-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP KMT2A 2738/4885GAA 1363/4885MGAM 3858/4885
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP KMT2A 2738/4885GAA 1363/4885MGAM 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.